AllDocs -> cancers

44 Mel Greaves PhD Hon MRCP FMedSci FRS Mel Greaves is Professor of Cell Biology and Section Chairman of Haemato-Oncology at The Institute of Cancer Research The challenge Acute leukaemia is the major subtype of paediatric cancer in developed societies. Each year in the UK, there are some 500 diagnoses of this disease which translates to an accumulative risk of around 1 in 2000 (between the ages of 0 and 15 years). Treatment of leukaemia in children, with combination chemotherapy in the context of controlled clinical trials, has been an extraordinary success story. Overall, cure rates are now around 80% but with variation between different cellular and molecular subtypes of the disease. Despite this progress, much remains to be achieved. Some subtypes of leukaemia remain refractory to effective eradication ...

MOLECULAR P A THOLOG Y – HAEMA T O-ONCOLOG Y 32 Understanding chronic lymphocytic leukaemia Advancing its diagnosis, prognosis and treatment Daniel Catovsky DSc(Med) FRCPath FRCP FMedSci Professor of Haematology A disease of variable guises C hronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in Western countries. Indeed, in the United Kingdom alone, there are about 2,700 new cases of CLL a year, and most occurrences are in adults, particularly those over the age of 60. CLL is a heterogeneous disease, having variable symptoms and a widely varying clinical course – thus making it difficult for clinicians to determine how it will evolve (ie its prognosis) and how best to treat. For instance, it is not unknown for some patients to be diagnosed, ...

Leukaemia Leukaemia is a cancer of blood-forming cells. Blood cells are made in bone marrow, the spongy part in the centre of the bone. Blood is mostly made up of plasma. Floating in the plasma are: • Red blood cells – that carry oxygen around the body • White blood cells – that fight disease and infection • Platelets – that help to stop bleeding when it starts. In people with leukaemia , the bone marrow produces large numbers of abnormal white blood cells. The abnormal white blood cells crowd into the bone marrow so the marrow can't make enough normal red blood cells, white blood cells and platelets. Over 630 Victorians develop leukaemia every year. Symptoms The symptoms of leukaemia may include: • Weakness and tiredness • Regular infections and high temperatures • Bleeding that takes a ...

Revised protocol - 27 th February 2001 CLL4 Chronic Lymphocytic Leukaemia Trial 4 A LRF sponsored trial from the MRC Adult Leukaemia Working Party. MREC (1) 98/101 A RANDOMISED COMPARISON OF CHLORAMBUCIL, FLUDARABINE AND FLUDARABINE PLUS CYCLOPHOSPHAMIDE. This new study will compare conventional therapy with chlorambucil versus the new agent fludarabine, used alone or in a novel combination with cyclophosphamide. End points of the trial will be: survival, response to therapy, duration of response, toxicity and quality of life. This protocol describes the MRC Adult Working Party protocol for CLL4 and the procedures for entering patients. For patients that require further treatment after relapse or second line therapy for non-responders, a second randomisation will compare treatment guided by the protocol versus guided by the in-vitro ...

Medsaic Pty Limited ACN: 094 771 141 Ph: +61 2 9209 4445 Suite 145, National Innovation Centre Fx: +61 2 9209 4646 Australian Technology Park, Garden Street Eveleigh, Sydney, NSW 1430 Australia Medsaic wins BioFirst Commercialisation Award for leukaemia diagnostic Sydney, Australia. 5 April 2005. Medsaic Pty Ltd was last night awarded the BioFirst Commercialisation Award for outstanding achievement in technology for its leukaemia and lymphoma diagnostic, DotScan. The BioFirst Commercialisation Award is given to the biotechnology company deemed most likely to achieve international success with its proof of concept technology. The BioFirst Commercialisation Award was established as part of the inaugural NSW First for Biotechnology Week , instigated by the NSW Department of State and Regional Development (DSRD) with other governmental and private sector stake holders ...

Fighting Childhood Leukaemia Page 2 2 Our research is carried out in the following centres of excellence throughout the UK. Leukaemia Research Fund 43 Great Ormond Street London WC1N 3JJ T: 020 7405 0101 F: 020 7405 3139 E: info@lrf.org.uk www.lrf.org.uk Registered charity 216032 SCOTLAND Dundee Glasgow Edinburgh NORTH WEST Manchester Liverpool NORTH EAST Newcastle Leeds Sheffield York MIDLANDS Birmingham Nottingham Leicester Oxford Cambridge This brochure has been produced thanks to the generosity of Deloitte staff and partners who have selected Leukaemia Research as their Charity of the Year 2005 - 2006. SOUTH WEST Bristol Salisbury SOUTH Southampton Bournemouth SOUTH EAST ...

LEUKAEMIA CLUSTERS Occasional Papers No 1. Occasional Papers is a series of short publications. which address topics of current concern or other wide public interest and which have been written for the non-specialist reader. ©1995 - The Royal Society of Edinburgh Published by the Leukaemia Research Fund with the kind permission of the Royal Society of Edinburgh Introduction and Summary Defining & Describing Clusters Statistical Principles British experience in the detection of human leukaemia clusters German experience in the observation of childhood leukaemia clusters The Nature & Possible Causes of Leukaemia Genetic Conspiracy Ionising Occasional Papers may be based on and published soon after a seminar, ...

Childhood leukaemia and powerlines Leukaemia Research statement Leukaemia Research response to the paper "Childhood cancer in relation to distance from high voltage power lines in England and Wales: a case-control study", BMJ 3 June 2005, Draper, Vincent et al: Commenting on the paper Dr David Grant, Scientific Director, Leukaemia Research, says: " Leukaemia Research recognises there is a lot of public anxiety and concern about living close to pylons and exposure to power-frequency magnetic fields. These fields are produced by the generation and use of electricity and are present in all homes with an electricity supply. "For this reason, we were the main charity involved with the United Kingdom Childhood Cancer Study (UKCCS), which is the largest and most comprehensive investigation of childhood leukaemia and other cancers ever undertaken anywhere in the world. This study has reported that there ...

Causation of Leukaemia Workshop 20 th – 21 st April 2005 9(%A,<%CD$<$'##=!+<*=$< !A=!A@<>+<3A&&A%C</=#>A""E<%CA< 4A' =A#D=<5A$A=!?C<0'&@<?"D&D?="<D&B(!#=%D(&<(BBD?A!<=&@<D$<&(%<=&< (BBD?D="<:3//7<@(?'#A&%<(!<!A(!% VebTorav ( >botbbp(88(]pa(887)qpbqcoebl]kdbmomorafbmfpoebtqklat]m`]kkfbaqrofp>kfo]fpoqmbbi oeb`]rmbmqc`eflaeqqa`]p`bk-Wmfpd`]p`bkkbdfmokfbm]paqoebkmqrk`bmoebmoravkb`krfoba]ll `eflakbp#rpabkoeb]dbqc(/]oaf]dpqmfm$fpFpdl]pa)T`qol]pa]paZ]lbmaf]dpqmbatfoe]pv cqknqc`]p`bk-@qpokql`eflakbp)n]o`ebacqk]db)mbu]pa]kb]qckbmfabp`b)tbkb]lmq kb`krfoba– oq^b`qnh]kbatfoeoeb]ccb`oba`eflakbp-Vefmovhbqcmorav)ipqtp]m]`]mb+ `qpokqlmorav)fmoeb]``bhobanboeqacqkmoravfpd`]rmbmqck]kbafmb]mbm-Jpcqkn]ofqp]^qro ^qoedkqrhmqc`eflakbp)`]mbm]pa`qpokql...

M yeloma is a life-threatening cancer of the blood, similar to leukaemia or lymphoma. It is caused when one type of blood cell, called a plasma cell, grows in uncontrolled numbers. Plasma cells, which grow in the bone marrow at the centre of many of our bones, play a vital role in our immune system, producing proteins which attack foreign bodies such as bacteria and other organisms. Unlike leukaemia where the tumour cells spill out into the blood, malignant myeloma cells accumulate in the bones. This build- up is most commonly found in bones closest to sites of the most active blood-forming bone marrow, such as the pelvis, spine and skull. The skeleton is not a static structure. Bone is continuously being formed and broken down again throughout life. Unfortunately, myeloma cells upset this fine balance which can lead to painful and debilitating bone damage which is such a distressing feature ...

DWIB Leukaemia Trust (UK) STANDING ORDER INSTRUCTION FORM For lack of knowledge our people are dying DWIB Leukaemia Trust is a Charity and a Company Limited By Guarantee No 05883298. Registered in England. Incorporated under the Companies Act 1985. Your Name: __ Your Address: __ __ __ __ Your Bank Details Name of your bank/building society: __ Address of your bank/building society: __ Postcode: __ Full name(s) of account holder(s): __ Your branch sort code number: - - Your current account number: My monthly/quarterly/annual* gift is £__ __ Start Date: __ (*Please delete as appropriate) (Date on which your standing order should begin) Your signature(s): __ Date: Instructions to bank/building society: Account Name: DWIB Leukaemia Trust Account number: ...

Statement of Principles concerning ACUTE MYELOID LEUKAEMIA No. 36 of 2006 for the purposes of the Veterans’ Entitlements Act 1986 and Military Rehabilitation and Compensation Act 2004 Title 1. This Instrument may be cited as Statement of Principles concerning acute myeloid leukaemia No. 36 of 2006. Determination 2. The Repatriation Medical Authority under subsection 196B(3) and (8) of the Veterans’ Entitlements Act 1986 (the VEA): (a) revokes Instrument No. 170 of 1996; and (b) determines in its place this Statement of Principles. Kind of injury, disease or death 3. (a) This Statement of Principles is about acute myeloid leukaemia and death from acute myeloid leukaemia . (b) For the purposes of this Statement of Principles, “acute myeloid leukaemia ” ...

Statement of Principles concerning ACUTE MYELOID LEUKAEMIA No. 35 of 2006 for the purposes of the Veterans’ Entitlements Act 1986 and Military Rehabilitation and Compensation Act 2004 Title 1. This Instrument may be cited as Statement of Principles concerning acute myeloid leukaemia No. 35 of 2006. Determination 2. The Repatriation Medical Authority under subsection 196B(2) and (8) of the Veterans’ Entitlements Act 1986 (the VEA): (a) revokes Instrument No. 169 of 1996; and (b) determines in its place this Statement of Principles. Kind of injury, disease or death 3. (a) This Statement of Principles is about acute myeloid leukaemia and death from acute myeloid leukaemia . (b) For the purposes of this Statement of Principles, “acute myeloid leukaemia ” ...

Haematopoiesis and Leukaemia Group Group Members Group Leader: Dr Owen Williams (Lecturer) Dr Michelle Morrow (Post Doctoral Fellow) Dr Meng-yong Yan (Post Doctoral Fellow Sarah Horton (PhD student) Vanessa Walf (PhD student) Our group is concerned with two main areas of research: Mechanisms of oncogenesis in infant and childhood leukaemia Chromosomal translocations are often associated with infant and childhood leukaemia . These translocations frequently result in the generation of a unique fusion gene. We are investigating the function of fusion genes that are commonly associated with infant and childhood acute lymphoblastic leukaemia (ALL) and infant acute myeloid leukaemia (AML). Translocations involving the Mixed Lineage Leukemia (MLL) gene on chromosome band 11q23 are most prevalent in infant leukemia where they comprise 80% of ...

Leukaemia , Haematopoiesis and Apoptosis Group Group Members Group Leader: Dr. Hugh Brady (Unit Head) Dr. Duncan Gascoyne (Post Doctoral Fellow) Dr. Jasper de Boer (Post Doctoral Fellow) Dr. Julianne Ellu (Post Doctoral Fellow) Dr. Anna Ruiz (Post Doctoral Fellow) Dr. Tanzina Chowdhury (Clinical Research Fellow) Dr. Ramya Ramanujachar (Clinical Research Fellow) Dr. Jenny Yeung (Research Fellow) Ellie Ashton (Experimental Officer) Martin Woodward (Research Assistant) Kathryn McMahon (PhD Student) Samira Salek Ardakani (PhD Student) Olga Solarska (PhD Student) Yeong-Lih Hiew (PhD Student) MLL and MLL fusions Gene targetting studies have demonstrated an essential role for Mll in mice. Mice homozygously null for the Mll gene die in utero and these Mll -/- embryos lack expression of major homeobox genes and exhibit defective ...

Patient management framework Haematological tumourstream: acute myeloid leukaemia a guide to consistent cancercare Page 2 Page 3 Patient management framework Haematological tumour stream: acute myeloid leukaemia Page 4 Published by Metropolitan Health and Aged Care Services Division, Victorian Government Department of Human Services, Melbourne Victoria Australia May 2006 © Copyright State ofVictoria, Department of Human Services, 2006. This publication is copyright. No part may be reproduced by any process except in accordance with the provisions of the Copyright Act 1968. Also published on www.health.vic.gov.au/cancer Authorised by the Victorian Government, 50 Lonsdale Street, Melbourne. Printed by GT Graphics Pty Ltd, 34 Stanley Street, Collingwood. Acknowledgements ...

Chapter 20: Leukaemia 193 Leukaemia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

leukaemia Dr Heather O Dickinson http://www.staff.ncl.ac.uk/heather.dickinson/ Department of Child Health University of Newcastle Cancer trends in England and Wales Deaths by cause (all ages), England & Wales, 1998 cancer 25% diseases of circulatory system 41% diseases of respiratory system 16% other 18% Age 1-4 yrs congenital anomalies Age 5-24 yrs accidents nervous system Age 25-74 yrs Over 75 yrs cancer respiratory system circulatory system other Deaths by cause and age group, 1998 5-year survival 0% 20% ...

l del file contenuto in http://www.supercourse.cn/SupercoursePPT/6011-7001/6301.ppt . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:g8QilRs_q0AJ:www.supercourse.cn/SupercoursePPT/6011-7001/6301.ppt+leukaemia+filetype:pdf+OR+filetype:doc+OR+filetype:ppt+OR+filetype:xls+OR+filetype:rtf&hl=it&ct=clnk&cd=339&lr=lang_en Google non è collegato agli autori di questa pagina e non è responsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: leukaemia Dr Heather O Dickinson My web page Department of Child Health University of Newcastle Audit of cancer registrations notified by National Health Service Central Register in England & Wales ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int ©EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 8 August 2006 Doc.Ref.: EMEA/COMP/137787/2006draft COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF decitabine for the treatment of acute myeloid leukaemia On 8 June 2006, orphan designation (EU/3/06/370) was granted by the European Commission to MGI Pharma Limited, United Kingdom, for decitabine for the treatment of acute myeloid leukaemia . What is acute myeloid leukaemia ? Acute myeloid leukaemia is ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int ©EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 8 August 2006 Doc.Ref.: EMEA/COMP/386781/2005 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF dasatinib for the treatment of acute lymphoblastic leukaemia On 23 December 2005, orphan designation (EU/3/05/338) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for dasatinib for the treatment of acute lymphoblastic leukaemia . What is acute lymphoblastic leukaemia ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int ©EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 8 August 2006 Doc.Ref.: EMEA/COMP/386800/2005 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF dasatinib for the treatment of chronic myeloid leukaemia On 23 December 2005, orphan designation (EU/3/05/339) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for dasatinib for the treatment of chronic myeloid leukaemia . What is chronic myeloid leukaemia ? Chronic ...

MEDIA RELEASE AUSTRALIAN LABOR PARTY Kelvin Thomson MP Shadow Minister for Public Accountability Shadow Minister for Human Services Wednesday, 9 August 2006 Out-of-touch Hockey ‘not briefed’ on shameful Leukaemia to Work case Human Services Minister, Joe Hockey, this morning showed that he is more focussed on his plastic Smartcard than the real life cases of his Centrelink customers, by admitting that he ‘hasn’t yet been briefed’ on the shameful treatment of leukaemia sufferer, Matthew Pearce. Out-of-touch Hockey refused an interview on ABC Radio because of a lack of a briefing and instead sent in the general manager of Centrelink to defend the indefensible. Minister Hockey claims he hasn’t been briefed despite: • Having a letter about the case forwarded to him by Minister Stone on Monday; • The case being on the front page of Matthew’s ...

1 Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulphate proteoglycan Nina Kureishy, Daisy Faruque and Colin D. Porter 1 The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK Running title: Primary attachment of MLV 1 Corresponding author: Dr. C. D. Porter, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK Telephone: +44 (0)207 153 5152 FAX: +44 (0)207 352 3299 e-mail: colin.porter@icr.ac.uk Biochemical Journal Immediate Publication. Published on 8 Aug 2006 as manuscript BJ20060825 Copyright 2006 Biochemical Society Page 2 2 SYNOPSIS Target cell entry of murine leukaemia virus vectors proceeds via primary attachment, independent of the viral envelope protein, and subsequent envelope/receptor ...

Infrastructure support for the Australasian Leukaemia and Lymphoma Group (ALLG) Trial Centre Enabling Grants Round 2 – Clinical Trials Infrastructure Support 1. Contact details: Chairman ALLG Peter MacCallum Cancer Centre St Andrews Place East Melbourne VIC 3002 Contact person: Dr John Seymour Email: John.Seymour@petermac.org Website: http://www.petermac.unimelb.edu.au/allg/ 2. Description of facility/activity: The grant provides infrastructure support for the operations of the Australasian Leukaemia and Lymphoma Group. The ALLG focuses on trials in the field of leukaemia , lymphoma, myeloma and related haematological malignancies. The group is open to all qualified haematologists and oncologists practising in Australia and New Zealand, and all trials are open to all members who are based at an institution with ...

J. Biosci., Vol. 11, Numbers 1—4, March 1987, pp. 543-548. © Printed in India. Abnormal erythrocyte membrane phospholipid organisation in chronic myeloid leukaemia A. KUMAR, S. DANIEL*, S. S. AGARWAL* and C. M. GUPTA† Division of Biochemistry, Central Drug Research Institute, Lucknow 226 001, India *Department of Medicine, King George's Medical College, Lucknow 226 003, India Abstract. The membrane phospholipid organisation in the red cells of humans suffering from chronic myeloid leukaemia has been analysed using the amino-group labelling reagent trinitrobenzenesulphonic acid and the fluid-sensing fluorophore, Merocyanine 540. Unlike the normal human erythrocytes, trinitrobenzenesulphonic acid in intact chronic myeloid leukaemia erythrocytes modified about 30% phosphatidylserine, under controlled conditions. Also, the chronic myeloid laukaemia red cells, but not the normal ...

CHRONIC MYELOID LEUKAEMIA FIFTH NATIONAL SEMINAR FOR PATIENTS AND CARERS Saturday 7th October 2006, Manchester Conference Centre Thank you for your enquiry about the fifth National Seminar for Patients with Chronic Myeloid Leukaemia and their carers. This is an annual event which is held at a different location every year, in the hope that as many people as possible affected by Chronic Myeloid Leukaemia will be able to come to a meeting. Every year there is more information available so please do feel free to attend even if you have already been to previous meetings. The meeting is intended to be fairly informal, but not everybody feels comfortable asking a national authority on CML a question in the middle of a big meeting! Because of this the meeting is divided into two parts. In the morning there will a series of talks in a large lecture theatre. After lunch, we will have breakout sessions, which ...

Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method CJ Hess 1 , F Denkers 1 , GJ Ossenkoppele 1 , Q Waisfisz 1 , CJ McElgunn 2 , E Eldering 3 , JP Schouten 2 and GJ Schuurhuis 1 1 Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands; 2 MRC-Holland, Hudsonstraat, Amsterdam, The Netherlands; and 3 Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands In acute myeloid leukaemia (AML), alterations in apoptotic pathways are crucial for treatment outcome, resulting either in refractoriness or in minimal residual disease (MRD). The apoptosis characteristics of MRD cells may differ from those at ...

For lack of knowledge our people are dying DWIB LEUKAEMIA TRUST (UK) ACCOUNT DETAILS FOR DONATIONS The DWIB Leukaemia Trust has been formed with the aim to increase awareness of leukaemia cancer and other blood disorders in the West African Sub-Region and create access to effective diagnostic and treatment resources for all. Most importantly, it aims to set up the first BONE MARROW REGISTER in West Africa, at the Korle-Bu Teaching Hospital. DONATE TO BANK Account Name: DWIB Leukaemia Trust Account Bank: Ghana International Bank Account Branch: 69 Cheapside, London, EC2P 2BB. Account No: 10111301 Sort Code: 60-92-63 SEND US A DONATION You can send a cheque or money order by post to mailing address: DWIB Leukaemia Trust 32 Pakington House, Crossford Street, London, SW9 9BA, UK. WE NEED ALL KINDS OF ...

Chronic Lymphocytic Leukaemia O N C O L O G Y 2 0 0 6 9 a report by Tapan Kadia , MD , Elias Jabbour , MD , and Susan O’Brien , MD Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston,Texas Introduction Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the western world, and is characterised by the clonal proliferation and accumulation of CD5 + B cells in the blood, marrow, lymph nodes and spleen. 1 An estimated 10,020 adults will be diagnosed with, and 4,660 will die of, CLL in the US in 2006. 2 Along with its high incidence, the chronic nature of the disease and its relatively longer survival make it one of the most prevalent of all ...